Myelin basic protein and index for neuro-Behçet's disease

Area of Science:

• Neuroimmunology
• Biomarker Discovery
• Central Nervous System Disorders

Background:

• Neuro-Behçet's disease (NBD) presents diagnostic challenges due to a lack of reliable biomarkers for intrathecal injury.
• Assessing central nervous system (CNS) myelin damage is crucial for understanding NBD prognosis.

Purpose of the Study:

• To evaluate the diagnostic utility of myelin basic protein (MBP) in distinguishing NBD patients from non-NBD neurological disease (NIND) controls.
• To assess MBP's potential in differentiating between acute and chronic progressive forms of NBD.

Main Methods:

• Measurement of paired cerebrospinal fluid (CSF) and serum MBP levels using ELISA.
• Calculation of an MBP index and correlation with established markers like IgG and albumin (Alb).

Main Results:

• CSF and serum MBP levels were significantly elevated in NBD patients compared to NIND.
• MBP demonstrated high specificity (>90%) in distinguishing NBD from NIND and differentiating acute from chronic NBD.
• MBP index showed a positive correlation with the IgG index, and serial monitoring indicated responsiveness to disease activity and treatment.

Conclusions:

• MBP serves as a valuable biomarker for diagnosing NBD, particularly in cases involving CNS demyelination.
• MBP can identify CNS pathogenic processes preceding clinical or imaging diagnosis, enabling earlier intervention.
• MBP monitoring offers insights into disease recurrence and therapeutic response in NBD.